Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsALFRY 75 5-Year Yield-on-Cost % is 4.10 as of Jul. 19, 2026, which is 27% above its 10-year median of 3.22. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.24 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 69 Medical Distribution companies, Alfresa Holdings ranks better than 50.72% on this metric.
Alfresa Holdings's yield on cost for the quarter that ended in Mar. 2026 was 4.10.
The historical rank and industry rank for Alfresa Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
ALFRY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.6 Med: 3.22 Max: 4.55
Current: 4.1
During the past 13 years, Alfresa Holdings's highest Yield on Cost was 4.55. The lowest was 1.60. And the median was 3.22.
ALFRY's 5-Year Yield-on-Cost % is ranked better than 50.72% of 69
companies
in the Medical Distribution industry
Industry Median: 3.66
vs ALFRY: 4.10
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alfresa Holdings 5-Year Yield-on-Cost % Related Terms
ALFRY vs MCK, CAH, COR: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Alfresa Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Alfresa Holdings (ALFRY) has a 5-Year Yield-on-Cost % of 4.10 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alfresa Holdings and its competitors. This is 27% above median its historical median of 3.22. Over the past decade, Alfresa Holdings' 5-Year Yield-on-Cost % has ranged from 1.60 to 4.55. According to the industry distribution chart, Alfresa Holdings ranks #34 out of 69 companies in the Medical Distribution industry, placing it in the top 49.3%.
Is Alfresa Holdings' 5-Year Yield-on-Cost % too high?
Alfresa Holdings' current 5-Year Yield-on-Cost % of 4.10 is 27% above median its 10-year median of 3.22. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 4.55. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.66. Alfresa Holdings' value of 4.10 is 12% above this industry median. Based on the distribution chart, Alfresa Holdings ranks #34 out of 69 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' 5-Year Yield-on-Cost % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #34 out of 69 companies for 5-Year Yield-on-Cost %. This puts Alfresa Holdings in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 3.66. Alfresa Holdings' value of 4.10 is 12% above this benchmark. Historically, Alfresa Holdings' own 5-Year Yield-on-Cost % has ranged from 1.60 to 4.55 over the past decade. While the company's 10-year median is 3.22 vs. the industry median of 3.66, Alfresa Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.66, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current 5-Year Yield-on-Cost % of 4.10 is 12% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current 5-Year Yield-on-Cost % is 4.10, which is 27% above median its own 10-year median of 3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.24, compared to a current price of $13.55 — trading 16.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.10, which is 27% above median its 10-year median of 3.22 and 12% above the Medical Distribution industry median of 3.66. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current 5-Year Yield-on-Cost % is 4.10 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.55 is trading 16.6% below its estimated GF Value™ of $16.24.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
5-Year Yield-on-Cost %: 4.10 (27% above median its 10-year median of 3.22)
GF Value™: $16.24 vs. price of $13.55 (16.6% below fair value)
Industry Position: 12% above the Medical Distribution median (#34 of 69)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
